Intelligent Bio Solutions Announces Completion of Usability Study

What Happened
On August 5, 2026, Intelligent Bio Solutions, Inc. (INBS) issued a press release—furnished as Exhibit 99.1 to a Current Report on Form 8‑K (Item 7.01)—announcing the completion of a usability study for its Intelligent Fingerprinting Drug Screening System. The company disclosed the development under Regulation FD; the Form 8‑K notes the press release text as the full disclosure.

Key Details

• Date of disclosure: August 5, 2026 (Form 8‑K filed with the SEC).
• Program: Usability study completed for the "Intelligent Fingerprinting Drug Screening System."
• Filing item: Regulation FD disclosure reported under Item 7.01; press release furnished as Exhibit 99.1.
• The Form 8‑K did not include financial results or other financial statements in connection with this announcement.

Why It Matters
This filing is a product development update signaling a completed usability study for INBS’s drug screening system—a milestone in demonstrating how the product performs for intended users. For investors, it is an operational progress report but not a financial disclosure: the 8‑K does not provide revenue, timing, regulatory filings, or commercialization details. Investors should view this as a factual update on product progress and look for subsequent releases for information on regulatory steps, timelines, or potential commercial impact.